Literature DB >> 32638014

Isoliquiritigenin inhibits TGF-β1-induced fibrogenesis through activating autophagy via PI3K/AKT/mTOR pathway in MRC-5 cells.

Jinjuan He1, Hao Peng2, Meifang Wang1, Ying Liu3, Xingrong Guo4, Bin Wang2,5, Longjun Dai2,5, Xueqin Cheng1, Zhongji Meng6, Leyong Yuan1, Fenglin Cai1, Yijun Tang1,4.   

Abstract

Isoliquiritigenin (ISL), a natural flavonoid derived from the root of liquorice, has been reported to possess anti-inflammatory and antioxidant activities. Previous studies have found that ISL plays a crucial role in anti-fibrosis of adipose tissue and renal tissue; however, its effect on pulmonary fibrogenesis has not been demonstrated. In this study, we aimed to explore the roles and the underlying mechanisms of ISL in TGF-β1-induced fibrogenesis using human lung fibroblast-derived MRC-5 cells. Cell proliferation and migration were determined by MTT and wound healing assay, respectively. The expression levels of alpha-smooth muscle actin (α-SMA), collagen type I alpha 1 (COLIA1) and fibronectin (FN), microtubule-associated protein light chain 3 (LC3) and related signaling molecules were detected by quantitative real-time PCR, western blot and immunofluorescence assay, correspondingly. EGFP-LC3 transfection was used for autophagy analysis. The results showed that ISL inhibited the TGF-β1-induced proliferation and migration, and down-regulated the expressions of α-SMA, COLIA1 and FN. ISL treatment led to up-regulation of LC3 in TGF-β1-treated MRC-5 cells, accompanied by significant decrease in the phosphorylation levels of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and mammalian target of rapamycin (mTOR). In addition, the inhibitory effects of ISL on TGF-β1-induced fibrogenic features in MRC-5 cells were enhanced by pretreatment with autophagy activator Rapmycin and PI3K/AKT inhibitor LY294002 and reversed by autophagy inhibitor 3-methyladenine and PI3K/AKT activator IGF-1. Taken together, our results demonstrated that ISL could attenuate the fibrogenesis of TGF-β1-treated MRC-5 cells by activating autophagy via suppressing the PI3K/AKT/mTOR pathway. Therefore, ISL holds a great potential to be developed as a novel therapeutic agent for the treatment of pulmonary fibrosis.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PI3K/AKT; TGF-β1; autophagy; isoliquiritigenin; mTOR; pulmonary fibrosis

Mesh:

Substances:

Year:  2020        PMID: 32638014     DOI: 10.1093/abbs/gmaa067

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  9 in total

1.  Autophagy in pulmonary fibrosis: friend or foe?

Authors:  Charlotte Hill; Yihua Wang
Journal:  Genes Dis       Date:  2022-11

2.  Prediction of the Mechanism of Sodium Butyrate against Radiation-Induced Lung Injury in Non-Small Cell Lung Cancer Based on Network Pharmacology and Molecular Dynamic Simulations and Molecular Dynamic Simulations.

Authors:  Xiao-Zhen Zhang; Mao-Jian Chen; Ping-Ming Fan; Ting-Shi Su; Shi-Xiong Liang; Wei Jiang
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

3.  Isoliquiritigenin Enhances the Beige Adipocyte Potential of Adipose-Derived Stem Cells by JNK Inhibition.

Authors:  Hanbyeol Moon; Jung-Won Choi; Byeong-Wook Song; Il-Kwon Kim; Soyeon Lim; Seahyoung Lee; Ki-Chul Hwang; Sang Woo Kim
Journal:  Molecules       Date:  2020-12-01       Impact factor: 4.411

Review 4.  TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review).

Authors:  Zhimin Ye; Yongbin Hu
Journal:  Int J Mol Med       Date:  2021-05-20       Impact factor: 4.101

5.  Inhibition of PI3K/AKT/mTOR Signalling Pathway Activates Autophagy and Suppresses Peritoneal Fibrosis in the Process of Peritoneal Dialysis.

Authors:  Miao Jia; Hong Qiu; Lihua Lin; Shun Zhang; Damei Li; Donghua Jin
Journal:  Front Physiol       Date:  2022-03-04       Impact factor: 4.566

6.  Network Pharmacology and Experimental Assessment to Explore the Pharmacological Mechanism of Qimai Feiluoping Decoction Against Pulmonary Fibrosis.

Authors:  Yingying Yang; Lu Ding; Tingting Bao; Yaxin Li; Jing Ma; Qingwei Li; Zezheng Gao; Siyu Song; Jing Wang; Jiachao Zhao; Ziyuan Wang; Daqing Zhao; Xiangyan Li; Zeyu Wang; Linhua Zhao; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

7.  Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation.

Authors:  Aijun Zhang; Yixuan Zou; Qingcui Xu; Shuo Tian; Jie Wang; Yilin Li; Renchao Dong; Liangzong Zhang; Juanjuan Jiang; Lili Wang; Kai Tao; Zhaoqing Meng; Yanqiu Liu
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

8.  Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.

Authors:  Qi-Dong Xia; Yang Xun; Jun-Lin Lu; Yu-Chao Lu; Yuan-Yuan Yang; Peng Zhou; Jia Hu; Cong Li; Shao-Gang Wang
Journal:  Cell Prolif       Date:  2020-11-03       Impact factor: 6.831

9.  Plumbagin attenuates traumatic tracheal stenosis in rats and inhibits lung fibroblast proliferation and differentiation via TGF-β1/Smad and Akt/mTOR pathways.

Authors:  Wei Shi; Yuanyuan Fang; Yueming Jiang; Siyang Jiang; Yu Li; Wentao Li; Mingpeng Xu; Michael Aschner; Guangnan Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.